Patients. Subjects. Participants. However we define them, the role they play in bringing new drugs to market is unquestionable. As such, drug developers the world ov...

The development of orally inhaled and nasal drug products (OINDPs) presents significant challenges, with failure rates of 70% and higher. This high failure rate stem...

As sustainability pressures drive innovation in pressurised Metered Dose Inhalers (pMDIs), the regulatory landscape must shift to accommodate new low carbon technolo...

The Evolution of Nasal Protection Solutions The global scientific community continues to advance research on COVID-19 and its long-term effects, commonly referred to...